company background image
A200230 logo

TELCON RF PHARMACEUTICAL KOSDAQ:A200230 Stock Report

Last Price

₩5.98k

Market Cap

₩71.9b

7D

0%

1Y

-28.3%

Updated

20 Dec, 2024

Data

Company Financials

TELCON RF PHARMACEUTICAL. Inc.

KOSDAQ:A200230 Stock Report

Market Cap: ₩71.9b

A200230 Stock Overview

Primarily engages in the development, production, and sale of RF coaxial connectors worldwide. More details

A200230 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

TELCON RF PHARMACEUTICAL. Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for TELCON RF PHARMACEUTICAL
Historical stock prices
Current Share Price₩5,980.00
52 Week High₩10,000.00
52 Week Low₩5,200.00
Beta-0.0084
1 Month Change3.28%
3 Month Change0.67%
1 Year Change-28.30%
3 Year Change-78.83%
5 Year Change-87.82%
Change since IPO-49.11%

Recent News & Updates

TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) Popularity With Investors Is Under Threat From Overpricing

Oct 23
TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) Popularity With Investors Is Under Threat From Overpricing

TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Could Be At Risk Of Shrinking As A Company

Sep 06
TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Could Be At Risk Of Shrinking As A Company

Recent updates

TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) Popularity With Investors Is Under Threat From Overpricing

Oct 23
TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) Popularity With Investors Is Under Threat From Overpricing

TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Could Be At Risk Of Shrinking As A Company

Sep 06
TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Could Be At Risk Of Shrinking As A Company

Investors Shouldn't Be Too Comfortable With TELCON RF PHARMACEUTICAL's (KOSDAQ:200230) Earnings

Mar 26
Investors Shouldn't Be Too Comfortable With TELCON RF PHARMACEUTICAL's (KOSDAQ:200230) Earnings

TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:200230) Investors Are Less Pessimistic Than Expected

Mar 13
TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:200230) Investors Are Less Pessimistic Than Expected

Is TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Using Too Much Debt?

Apr 05
Is TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Using Too Much Debt?

Did Business Growth Power TELCON RF PHARMACEUTICAL's (KOSDAQ:200230) Share Price Gain of 218%?

Feb 03
Did Business Growth Power TELCON RF PHARMACEUTICAL's (KOSDAQ:200230) Share Price Gain of 218%?

Shareholder Returns

A200230KR ElectronicKR Market
7D0%2.3%-1.6%
1Y-28.3%-28.7%-9.1%

Return vs Industry: A200230 matched the KR Electronic industry which returned -28.7% over the past year.

Return vs Market: A200230 underperformed the KR Market which returned -9.1% over the past year.

Price Volatility

Is A200230's price volatile compared to industry and market?
A200230 volatility
A200230 Average Weekly Movement6.2%
Electronic Industry Average Movement6.4%
Market Average Movement6.6%
10% most volatile stocks in KR Market12.6%
10% least volatile stocks in KR Market3.3%

Stable Share Price: A200230 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A200230's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1999127Jin-Hun Limwww.telcon.co.kr

TELCON RF PHARMACEUTICAL. Inc. primarily engages in the development, production, and sale of RF coaxial connectors worldwide. It also provides coaxial couplers, distributors, and arresters, as well as cable assemblies; and pharmaceuticals.

TELCON RF PHARMACEUTICAL. Inc. Fundamentals Summary

How do TELCON RF PHARMACEUTICAL's earnings and revenue compare to its market cap?
A200230 fundamental statistics
Market cap₩71.91b
Earnings (TTM)-₩10.05b
Revenue (TTM)₩36.95b

1.9x

P/S Ratio

-7.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A200230 income statement (TTM)
Revenue₩36.95b
Cost of Revenue₩27.88b
Gross Profit₩9.08b
Other Expenses₩19.12b
Earnings-₩10.05b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-835.57
Gross Margin24.56%
Net Profit Margin-27.19%
Debt/Equity Ratio43.9%

How did A200230 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 20:49
End of Day Share Price 2024/12/09 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

TELCON RF PHARMACEUTICAL. Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yang Ju ParkDaishin Securities Co. Ltd.